Correction: The influence of FCGR2A and FCGR3A polymorphisms on the survival of patients with recurrent or metastatic squamous cell head and neck cancer treated with cetuximab

Correction: The influence of FCGR2A and FCGR3A polymorphisms on the survival of patients with recurrent or metastatic squamous cell head and neck cancer treated with cetuximabCorrection: The influence of FCGR2A and FCGR3A polymorphisms on the survival of patients with recurrent or metastatic squamous cell head and neck cancer treated with cetuximab, Published online: 18 January 2019; doi:10.1038/s41397-019-0073-5Correction: The influence of FCGR2A and FCGR3A polymorphisms on the survival of patients with recurrent or metastatic squamous cell head and neck cancer treated with cetuximab

Source: The Pharmacogenomics Journal - January 18, 2019 Category: Drugs & Pharmacology Authors: T. Magnes T. Melchardt C. Hufnagl L. Weiss C. Mittermair D. Neureiter E. Klieser G. Rinnerthaler S. Roesch A. Gaggl R. Greil A. Egle Source Type: research